Kjell Öberg
- Epidemiology top 0.01%
- Oncology top 0.02%
- Neurology top 0.01%
- Molecular Biology top 2%
- Surgery top 1%
- Co-authors
- Barbro ErikssonBritt SkogseidEva Tiensuu JansonMarianne PavelAnders SundinErik WilanderMats StridsbergAurel Perren
- Topics
- Neuroendocrine Tumor Research Advances (340 papers)Neuroblastoma Research and Treatments (229 papers)Lung Cancer Research Studies (174 papers)
- Cited by
- NeurologyOncologyEpidemiology
- Partner nations
- SwedenUnited StatesGermany
In The Last Decade
Kjell Öberg
389 papers receiving 25.4k citations
Hit Papers
Peers
Comparison fields: 5 of 165
- Epidemiology 20.6k
- Oncology 18.2k
- Neurology 14.5k
- Molecular Biology 2.8k
- Surgery 2.3k
Countries citing papers authored by Kjell Öberg
This map shows the geographic impact of Kjell Öberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kjell Öberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kjell Öberg more than expected).
Fields of papers citing papers by Kjell Öberg
This network shows the impact of papers produced by Kjell Öberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kjell Öberg. The network helps show where Kjell Öberg may publish in the future.
Co-authorship network of co-authors of Kjell Öberg
This figure shows the co-authorship network connecting the top 25 collaborators of Kjell Öberg. A scholar is included among the top collaborators of Kjell Öberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kjell Öberg. Kjell Öberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 13 | |
| 2 | Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upbreakdown → | 653 |
| 3 | Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs : Analysis of the Completed TELESTAR Extension Period | 2 |
| 4 | QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors | 3 |
| 5 | NETTER-1 Phase III Trial : Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors | 2 |
| 6 | 192 | |
| 7 | Patient Interviews in TELESTAR, a Phase 3 Study of Telotristat Etiprate, Report Meaningful Improvement in Carcinoid Syndrome | 1 |
| 8 | Telotristat etiprate shows benefit in treating patients With carcinoid syndrome that is inadequately controlled by somatostatin analog therapy in the phase 3 TELESTAR clinical trial | 1 |
| 9 | Assessing Treatment Benefit of Telotristat Etiprate in Patients with Carcinoid Syndrome : Patient Exit Interviews | 1 |
| 10 | Olfactory Receptor 51E1 is a Potential Novel Tissue Biomarker for the Diagnosis of Small Intestine Neuroendocrine Tumors | 4 |
| 11 | Treatment of Pancreatic Neuroendocrine Tumors (pNET) With Everolimus: Improved Progression-Free Survival Compared With Placebo (RADIANT-3) | 1 |
| 12 | PROGNOSTIC AND PREDICTIVE VALUE OF CHROMOGRANIN A AND NEURON-SPECIFIC ENOLASE IN PATIENTS (PTS) WITH ADVANCED PANCREATIC NEUROENDOCRINE TUMORS (PNET) TREATED WITH EVEROLIMUS | 11 |
| 13 | The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro. | 34 |
| 14 | Efficacy, Safety and Pharmacokinetic Results from a Phase II Study of Pasireotide (SOM230) in the Treatment of Patients with Metastatic NETs Refractory or Resistant to Octreotide LAR | 5 |
| 15 | 41 | |
| 16 | 21 | |
| 17 | Role of somatostatin analogues in oncology : European Neuroendocrine Tumour Network (ENET), February 24-27, 2000, Innsbruck, Austria/ guest editor, Kjell Oberg | 1 |
| 18 | Positron emission tomography (PET) with 5-hydroxytryptophan (5-HTP) in the diagnosis and treatment follow upp of carcinoid tumors | 10 |
| 19 | 11 | |
| 20 | Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. | 68 |
About Kjell Öberg
Kjell Öberg is a scholar working on Neurology, Epidemiology and Oncology, having authored 402 papers that have together received 26.1k indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (340 papers), Neuroblastoma Research and Treatments (229 papers) and Lung Cancer Research Studies (174 papers). The work is most often cited by research in Neurology (14.5k citations), Oncology (18.2k citations) and Epidemiology (20.6k citations). Kjell Öberg has collaborated with scholars based in Sweden, United States and Germany. Frequent co-authors include Barbro Eriksson, Britt Skogseid, Eva Tiensuu Janson, Marianne Pavel, Anders Sundin, Erik Wilander, Mats Stridsberg, Aurel Perren, Göran Åkerström and Edward M. Wolin. Their work appears in journals such as Nature, New England Journal of Medicine and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.